アスピリンによる抗血小板作用の Pharmacodynamics に関する情報学的研究 : 血小板中および血管内皮細胞中シクロオキシゲナーゼ阻害作用を考慮した Pharmacodynamic Model の構築

概要

論文の詳細を見る
The pharmacokinetic-pharmacodynamic model for ascertaining the antiplatelet effect of aspirin was developed, considering the effect of aspirin on the metabolic turnover of cyclooxygenase in platelets and vessel wall endothelium. All date used for analysis were obtained from the literature. The pharmacodynamic parameters, K, K', ke and ke as reaction rate constants of aspirin and cyclooxygenase in platelets and that in endothelium, and the turnover rate constants of cyclooxygenase in platelets and that in endothelium, respectively, were calculated based on the plasma aspirin concentration profile, the plasma thromboxane B_2 concentration as the index of inhibition of cyclooxygenase in platelets and the reduction of prostacyclin production of venous tissue as the index of inhibition of cyclooxygenase in vessel wall endothelium. The values of K and K'were 3.21 and 0. 97 ml・μg^<-1>・hr^<-1>, respectively, demonstrating selectivity of aspirin to cyclooxygenase in platelets. The value of ke was 0. 00630 hr^<-1>, which was consistent with the platelet life span. The developed model could explain the long duration of antiplatelet activity of aspirin and may be useful for formulating a rational dosage regimen for effective antiplatelet therapy utilizing aspirin.
日本医療薬学会の論文
1996-04-10